BMS-833923 (XL139)

DRUG2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Basal Cell Carcinoma (BCC)Basal Cell Nevoid Syndrome (BCNS)CancerHedgehog PathwaySmoothened

Phase 1

A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

CompletedNCT00670189

Bristol-Myers SquibbBasal Cell Carcinoma (BCC), Basal Cell Nevoid Syndrome (BCNS), Hedgehog Pathway +1

Start: 2008-07-31End: 2014-05-31Updated: 2014-08-15

Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors

CompletedNCT01413906

Bristol-Myers SquibbCancer

Start: 2011-11-30End: 2012-11-30Updated: 2013-06-03